A Phase 3 interventional study of Boostrix® and Decavac™ in Tetanus, Acellular Pertussis and Diphtheria, sponsored by GlaxoSmithKline. Completed at 24 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-03.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.
Among the 22 studies testing boostrix in Tetanus, this one is the 5th largest by enrollment, is the only one that started in 2009, is one of 12 in phase 3, and was the 10th registered.
318 studies on the registry are indexed under Tetanus; 29 are open to participants now.
Browse Tetanus studies →2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2009.
This study's enrollment of 1,332 is above the median of 418 across 280 interventional studies indexed under Tetanus.
Median enrollment 554 across the 22 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
106 studies in Tetanus by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 104 finished, 62 (60%) have results posted.
Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 9th largest by enrollment of the 98 interventional ones that give a count, is one of 6 that started in 2009, is one of 60 in phase 3, and was the 51st registered.
GlaxoSmithKline’s Tetanus studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing boostrix in Tetanus, from their registry updates:
Among GlaxoSmithKline’s 106 in Tetanus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)
Biological: Boostrix®
Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)
Biological: Decavac™
Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value
Antibodies against vaccine antigens assessed were: anti-diphtheria (anti-D) and anti-tetanus (anti-T). Anti-D antibody cut-off value assessed was ≥ 0.1 International Unit per milliliter (IU/mL) Anti-T antibody cut-off values assessed were ≥ 0.1 IU/mL and ≥ 1.0 IU/mL
Time frame: One month after vaccination.
Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration
Concentration for anti-PT, anti-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per millilitre (EL.U/mL)
Time frame: Before (PRE) and one month after vaccination (POST)
Anti-T and Anti-D Antibody Concentrations
Concentrations for anti-T and anti-D antibodies given as GMC in IU/mL.
Time frame: Before (PRE) and one month after vaccination (POST)
Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off
Booster response defined as : For initially seronegative subjects (\< 0.1 IU/mL), antibody concentration ≥ 0.4 IU/mL one month after vaccination. For initially seropositive subjects (≥ 0.1 IU/mL): antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Time frame: One month after vaccination
Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off
Booster response defined as : For initially seronegative subjects (\< 5 EL.U/mL), antibody concentration ≥ 20 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration \< 20 EL.U/mL: antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration ≥ 20 EL.U/mL : antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.
Time frame: One month after vaccination
Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.
Vaccine response using alternative definitions defined as: For initially seronegative subjects (\< 5 EL.U/mL ), antibody concentration ≥ 10 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL), antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.
Time frame: One month after vaccination
Number of Subjects Reporting Solicited Local Symptoms
Solicited local symptoms assessed include pain, redness and swelling.
Time frame: Within the 4-day (Day 0-3) post-vaccination period
Number of Subjects Reporting Solicited General Symptoms
Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, and fever
Time frame: Within the 4-day (Day 0-3) post-vaccination period
Number of Subjects Reporting Unsolicited Adverse Events (AE)
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Within the 31-day (Day 0-30) post-vaccination period
Number of Subjects Reporting Serious Adverse Events (SAE)
An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
Time frame: From the vaccination up to Day 182
| Milestone | Boostrix Group | Decavac Group |
|---|---|---|
| Started | 887 | 445 |
| Completed | 881 | 445 |
| Not completed | 6 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
Antibodies against vaccine antigens assessed were: anti-diphtheria (anti-D) and anti-tetanus (anti-T). Anti-D antibody cut-off value assessed was ≥ 0.1 International Unit per milliliter (IU/mL) Anti-T antibody cut-off values assessed were ≥ 0.1 IU/mL and ≥ 1.0 IU/mL
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Anti-D (≥ 0.1 IU/mL) (N= 859;432) | 729 | 374 |
| Anti-T (≥ 0.1 IU/mL) (N= 864;439) | 836 | 428 |
| Anti-T (≥ 1.0 IU/mL) (N= 864;439) | 767 | 395 |
Concentration for anti-PT, anti-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per millilitre (EL.U/mL)
| EL.U/mL | Boostrix Group | Decavac Group |
|---|---|---|
| Anti-PT (PRE) (N=859;433) | 6.6 (6.1 to 7.1) | 6.5 (5.8 to 7.2) |
| Anti-PT (POST) (N=852;431) | 49.1 (44.9 to 53.7) | 6.4 (5.8 to 7.1) |
| Anti-FHA (PRE) (N=848;430) | 50.2 (46.2 to 54.5) | 44.3 (39.5 to 49.5) |
| Anti-FHA (POST) (N=835;428) | 689.0 (638.8 to 743.1) | 44.4 (39.7 to 49.7) |
| Anti-PRN (PRE) (N=864;439) | 8.1 (7.4 to 8.8) | 7.8 (6.9 to 8.8) |
| Anti-PRN (POST) (N=865;439) | 104.2 (91.3 to 118.9) | 7.7 (6.8 to 8.7) |
Concentrations for anti-T and anti-D antibodies given as GMC in IU/mL.
| IU/mL | Boostrix Group | Decavac Group |
|---|---|---|
| Anti-D (PRE) (N=844;430) | 0.2 (0.2 to 0.2) | 0.2 (0.1 to 0.2) |
| Anti-D (POST) (N=859;432) | 0.9 (0.8 to 1.0) | 0.8 (0.7 to 1.0) |
| Anti-T (PRE) (N=864;439) | 0.6 (0.6 to 0.7) | 0.6 (0.5 to 0.7) |
| Anti-T (POST) (N=864;439) | 4.0 (3.6 to 4.3) | 7.1 (6.1 to 8.1) |
Booster response defined as : For initially seronegative subjects (\< 0.1 IU/mL), antibody concentration ≥ 0.4 IU/mL one month after vaccination. For initially seropositive subjects (≥ 0.1 IU/mL): antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Anti-D (N=842;428) | 383 | 189 |
| Anti-T (N=863;439) | 438 | 306 |
Booster response defined as : For initially seronegative subjects (\< 5 EL.U/mL), antibody concentration ≥ 20 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration \< 20 EL.U/mL: antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration ≥ 20 EL.U/mL : antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Anti-PT (N=846;430) | 585 | 430 |
| Anti-FHA (N=821;422) | 762 | 7 |
| Anti-PRN (N=864;439) | 638 | 9 |
Vaccine response using alternative definitions defined as: For initially seronegative subjects (\< 5 EL.U/mL ), antibody concentration ≥ 10 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL), antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Anti-PT (N=846;430) | 699 | 9 |
| Anti-FHA (N=821;422) | 765 | 8 |
| Anti-PRN (N=864;439) | 714 | 11 |
Solicited local symptoms assessed include pain, redness and swelling.
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Pain | 190 | 123 |
| Redness | 95 | 56 |
| Swelling | 66 | 52 |
Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, and fever
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Fatigue | 110 | 66 |
| Gastrointestinal symptoms | 67 | 41 |
| Headache | 101 | 52 |
| Fever | 18 | 11 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Number of Subjects Reporting Unsolicited Adverse Events (AE) | 152 | 64 |
An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
| subjects | Boostrix Group | Decavac Group |
|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAE) | 37 | 10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boostrix Group | — | 37/887 (4.2%) | 351/887 (39.6%) |
| Decavac Group | — | 10/445 (2.2%) | 202/445 (45.4%) |
| Event | Boostrix Group | Decavac Group |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 3/887 | 0/445 |
| Myocardial infarctionCardiac disorders | 2/887 | 1/445 |
| Cerebrovascular accidentNervous system disorders | 2/887 | 0/445 |
| Hip fractureInjury, poisoning and procedural complications | 2/887 | 0/445 |
| PneumoniaInfections and infestations | 2/887 | 0/445 |
| Transient ischaemic attackNervous system disorders | 2/887 | 0/445 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/887 | 1/445 |
| Atrioventricular block completeCardiac disorders | 0/887 | 1/445 |
| Breast cancer in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/887 | 1/445 |
| DementiaNervous system disorders | 0/887 | 1/445 |
| Event | Boostrix Group | Decavac Group |
|---|---|---|
| PainGeneral disorders | 190/887 | 123/445 |
| FatigueGeneral disorders | 110/887 | 66/445 |
| RednessGeneral disorders | 95/887 | 56/445 |
| SwellingGeneral disorders | 66/887 | 52/445 |
| HeadacheGeneral disorders | 101/887 | 52/445 |
| Gastrointestinal symptomsGeneral disorders | 67/887 | 41/445 |
| Age, Continuous(years) | Boostrix Group | Decavac Group | Total |
|---|---|---|---|
| Mean | 71.6 ± 5.35 | 71.9 ± 5.62 | 71.7 ± 5.44 |
| Sex: Female, Male(Participants) | Boostrix Group | Decavac Group | Total |
|---|---|---|---|
| Female | 478 | 237 | 715 |
| Male | 409 | 208 | 617 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Feb 2009 to primary completion in Jul 2009, 5 months.
Results were first posted in Aug 2010, 1 year after primary completion.
Of 55 industry-sponsored phase 3 interventional studies under Tetanus, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's 5 months is below that.
Counting every sponsor, half of 56 studies reached it within 12 months; a quarter within 6 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix